{"id":16759,"date":"2022-01-04T16:32:15","date_gmt":"2022-01-04T16:32:15","guid":{"rendered":"https:\/\/psychedelichealth.co.uk\/?p=16759"},"modified":"2022-01-04T16:32:15","modified_gmt":"2022-01-04T16:32:15","slug":"simultaneous-administration-of-psilocybin","status":"publish","type":"post","link":"https:\/\/psychedelichealth.co.uk\/2022\/01\/04\/simultaneous-administration-of-psilocybin\/","title":{"rendered":"First-of-its-kind trial investigates simultaneous administration of psilocybin"},"content":{"rendered":"

Results from a new study have demonstrated that 10mg or 25mg doses of psilocybin have no long- or short-term detrimental effects in healthy individuals.\u00a0<\/span><\/b><\/h3>\n

In an essential first step in demonstrating the safety and feasibility of psilocybin, a new study has shown the compound can be safely administered in 10mg or 25mg doses to up to six participants simultaneously.<\/p>\n

The study is the first of its kind to investigate the simultaneous administration of psilocybin for use within controlled settings alongside talking therapy as a potential treatment for conditions such as treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD).<\/p>\n

The research<\/a>, from the Institute of Psychiatry, Psychology, & Neuroscience (IoPPN) at King\u2019s College London<\/a>, carried out in partnership with UK company COMPASS Pathways<\/a>, has been published in The Journal of Psychopharmacology<\/i><\/a>.<\/p>\n